On January 30, 2020, the Board of Directors of Orchard Therapeutics plc elected Dr. Steven Altschuler to the Board as a Class II director of the Company, effective as of February 3, 2020, and appointed him to serve on the Board’s Science and Technology Committee. Class II directors are appointed to serve until the 2020 annual general meeting. Dr. Altschuler brings nearly 20 years of experience building and integrated, translational, value-based health care systems and transformational biotechnology companies. He currently serves as managing director of Healthcare Ventures at Ziff Capital Partners and was previously chair of the board of directors at Spark Therapeutics (now part of Roche) for six years, from its founding until it was acquired in 2019.